Downregulation of microRNA-214 and overexpression of FGFR-1 contribute to hepatocellular carcinoma metastasis

Biochemical and Biophysical Research Communications

Volumn 439, Issue 1, 2013, Pages 47-53

  Wang, Jian ^a   Li, Jingwu ^b,c   Wang, Xiuchao ^a   Zheng, Chen ^a   Ma, Weidong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TANGSHAN PEOPLE S HOSPITAL   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

FGFR 1; Hepatocellular carcinoma; Metastasis; MiR 214

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; LUCIFERASE; MICRORNA 214;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOWN REGULATION; EARLY CANCER; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

FGFR-1; HEPATOCELLULAR CARCINOMA; METASTASIS; MIR-214;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECURRENCE; TRANSFECTION;

EID: 84883826034     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.08.032     Document Type: Article

References (30)

1. Huang G., Lai E.C., Lau W.Y., Zhou W.P., Shen F., Pan Z.Y., Fu S.Y., Wu M.C. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann. Surg. 2013, 257:490-505.
2. Li Q., Wang J., Juzi J.T., Sun Y., Zheng H., Cui Y., Li H., Hao X. Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J. Gastrointest. Surg. 2008, 12:1540-1547.
3. Fan H.L., Chen T.W., Hsieh C.B., Jan H.C., His S.C., De-Chuan C., Chu C.H., Yu J.C. Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria. Am. J. Surg. 2010, 200:252-257.
4. Yang Y., Nagano H., Ota H., Morimoto O., Nakamura M., Wada H., Noda T., Damdinsuren B., Marubashi S., Miyamoto A., Takeda Y., Dono K., Umeshita K., Nakamori S., Wakasa K., Sakon M., Monden M. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007, 141:196-202.
5. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S., Calin G.A. MicroRNAs - the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9:293-302.
6. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
7. Trujillo R.D., Yue S.B., Tang Y., O'Gorman W.E., Chen C.Z. The potential functions of primary microRNAs in target recognition and repression. EMBO J. 2010, 29:3272-3285.
8. Law P.T., Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J. Gastroenterol Hepatol. 2011, 26:437-449.
9. Shi W., Gerster K., Alajez N.M., Tsang J., Waldron L., Pintilie M., Hui A.B., Sykes J., P'ng C., Miller N., McCready D., Fyles A., Liu F.F. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011, 71:2926-2937.
10. Donnem T., Lonvik K., Eklo K., Berg T., Sorbye S.W., Al-Shibli K., Al-Saad S., Andersen S., Stenvold H., Bremnes R.M., Busund L.T. Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer 2011, 117:3193-3200.
11. Scisciani C., Vossio S., Guerrieri F., Schinzari V., De Iaco R., D'Onorio de Meo P., Cervello M., Montalto G., Pollicino T., Raimondo G., Levrero M., Pediconi N. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J. Hepatol. 2012, 56:855-861.
12. Shen G., Jia H., Tai Q., Li Y., Chen D. MiR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis 2013, 34:211-219.
13. Zhou L., Yang Z.X., Song W.J., Li Q.J., Yang F., Wang D.S., Zhang N., Dou K.F. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int. J. Oncol. 2013, 43:661-669.
14. Wang Y., Lee A.T., Ma J.Z., Wang J., Ren J., Yang Y., Tantoso E., Li K.B., Ooi L.L., Tan P., Lee C.G. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J. Biol. Chem. 2008, 283:13205-13215.
15. Wang X., Chen J., Li F., Lin Y., Zhang X., Lv Z., Jiang J. MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin. Biochem. Biophys. Res. Commun. 2012, 428:525-531.
16. Shih T.C., Tien Y.J., Wen C.J., Yeh T.S., Yu M.C., Huang C.H., Lee Y.S., Yen T.C., Hsieh S.Y. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J. Hepatol. 2012, 57:584-591.
17. Cheng A.L., Shen Y.C., Zhu A.X. Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology 2011, 81:372-380.
18. Ogasawara S., Yano H., Iemura A., Hisaka T., Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996, 24:198-205.
19. Wang J., Li J., Shen J., Wang C., Yang L., Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12:227.
20. Yang F., Zhang Y., Ressler S.J., Ittmann M.M., Ayala G.E., Dang T.D., Wang F., Rowley D.R. FGFR-1 is essential for prostate cancer progression and metastasis. Cancer Res. 2013, 73:3716-3724.
21. Tiburcio M., Costa S.M., DE Fatima Duarte M., Schmitt F.C., Longatto Filho A. Characterization of PAR1 and FGFR-1 expression in invasive breast carcinomas: prognostic significance. Oncol. Lett. 2012, 4:647-657.
22. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis-Filho J.S., Ashworth A. FGFR-1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70:2085-2094.
23. Udayakumar T.S., Nagle R.B., Bowden G.T. Fibroblast growth factor-1 transcriptionally induces membrane type-1 matrix metalloproteinase expression in prostate carcinoma cell line. Prostate 2004, 58:66-75.
24. Li B., Han Q., Zhu Y., Yu Y., Wang J., Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting twist. FEBS J. 2012, 279:2393-2398.
25. Peng R.Q., Wan H.Y., Li H.F., Liu M., Li X., Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-α-d-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J. Biol. Chem. 2012, 287:14301-14309.
26. Selbach M., Schwanhäusser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
27. Deng M., Ye Q., Qin Z., Zheng Y., He W., Tang H., Zhou Y., Xiong W., Zhou M., Li X., Yan Q., Ma J., Li G. miR-214 promotes tumorigenesis by targeting lactotransferrin in nasopharyngeal carcinoma. Tumour Biol. 2013, 34:1793-1800.
28. Xu C.X., Xu M., Tan L., Yang H., Permuth-Wey J., Kruk P.A., Wenham R.M., Nicosia S.V., Lancaster J.M., Sellers T.A., Cheng J.Q. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J. Biol. Chem. 2012, 287:34970-34978.
29. Kumar P., Luo Y., Tudela C., Alexander J.M., Mendelson C.R. The c-Myc-regulated microRNA-17~92 (miR-17~92) and miR-106a~363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol. Cell. Biol. 2013, 33:1782-1796.
30. Chien W.W., Domenech C., Catallo R., Kaddar T., Magaud J.P., Salles G., Ffrench M. Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway. Oncogene 2011, 30:1880-1891.